Extended Depth of Field Intraocular Lens for Cataract After Vitrectomy for Retinal Detachment: A Prospective Trial Authors: Efstathios Vounotrypidis, Dorian Begaj, Rupert Kamnig, Julie Meyer, Melih Parlak, Christian M. Wertheimer, Armin Wolf Published: 2026 ABSTRACT IntroductionThis study aimed to evaluate visual outcomes and patient satisfaction following implantation of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in eyes with cataract developing after pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD).MethodsPatients who underwent PPV for RRD, with or without macular involvement, and subsequently developed cataract were prospectively enrolled. Cataract surgery was performed with implantation of the Vivity EDOF-IOL (Alcon). Bilateral implantation was performed according to patient preference. Inclusion criteria were attached retina 3–6 months after PPV and corrected distant visual acuity of 0.3–0.7 logMAR. Primary outcomes were monocular and binocular, corrected and uncorrected distance, intermediate, and near visual acuity (CDVA, UDVA, DCIVA, UIVA, DCNVA, UNVA) at 6 months. Secondary outcomes included defocus curve and patient-reported satisfaction.ResultsTwenty-seven patients (43 eyes) underwent surgery at 6 ± 3 months after PPV (16 patients bilateral). Thirteen patients had RRD with macular involvement. In the RRD-affected eyes CDVA improved statistically significantly from 0.35 ± 0.16 to 0.03 ± 0.12 and UDVA from 1.01 ± 0.34 to 0.16 ± 0.19 logMAR at 6 months. Mean visual acuities at 6 months for RRD-affected eyes were DCIVA 0.53 ± 0.21, UIVA 0.44 ± 0.15, DCNVA 0.59 ± 0.23, and UNVA 0.47 ± 0.23 logMAR. Binocular UDVA, UIVA, and UNVA for the bilateral cases were − 0.04 ± 0.11, 0.29 ± 0.10, and 0.26 ± 0.13 logMAR, respectively. The defocus curve was comparable between macula-on, macula-off, and fellow eyes. Patient satisfaction was favorable with just two patients reporting halos.ConclusionUsing the Vivity EDOF-IOL in selected patients with cataract after successful PPV for RRD appears to be a safe and effective option, yielding favorable visual outcomes regardless of macular involvement.Trial Registration NumberDRKS00037029.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40123-026-01461-7. Key Summary Points Why carry out this study?Presbyopia-correcting intraocular lenses (IOL) are generally contraindicated in eyes with diseases affecting the central retina.This study evaluates if the Vivity extended depth of focus (EDOF) IOL can provide good results in retinal disease after applying careful patient selection criteria.What was learned from the study?The Vivity EDOF-IOL shows good functional results in eyes after successful anatomical retinal detachment (RRD) repair with or without macular involvement.The Vivity EDOF-IOL shows a comparable defocus curve in post-RRD and fellow eyes.Patient satisfaction is high with low frequency of reported photic phenomena. Why carry out this study?Presbyopia-correcting intraocular lenses (IOL) are generally contraindicated in eyes with diseases affecting the central retina.This study evaluates if the Vivity extended depth of focus (EDOF) IOL can provide good results in retinal disease after applying careful patient selection criteria.What was learned from the study?The Vivity EDOF-IOL shows good functional results in eyes after successful anatomical retinal detachment (RRD) repair with or without macular involvement.The Vivity EDOF-IOL shows a comparable defocus curve in post-RRD and fellow eyes.Patient satisfaction is high with low frequency of reported photic phenomena. Introduction Modern cataract surgery is accompanied by high patient expectations for spectacle independence and presbyopia correction [1,2]. Multifocal intraocular lenses (IOLs) reduce glasses dependency for distance, intermediate, and near vision. However, these lenses may be associated with drawbacks such as decreased contrast sensitivity and disturbing visual phenomena such as glare [3,4]. In comparison to providing multiple foci through diffractive optics, extended depth of focus (EDOF) IOLs create a single elongated focal point in order to address these limitations [5]. These lenses are designed to provide good distance and intermediate visual acuity, while reducing the incidence of unwanted visual phenomena compared to multifocal IOLs [5]. As concomitant ocular diseases may reduce contrast sensitivity, most surgeons desist from use of multifocal IOLs in such cases. Therefore, retinal or macular pathology is typically viewed as a contraindication for multifocal or EDOF-IOL implantation. However, by providing fewer side effects, EDOF-IOLs are currently being explored in patients with pre-existing retinal pathologies such as low-grade epiretinal membrane (ERM) or in combination with ERM surgery [6,7]. A recent study demonstrated comparable visual outcomes between eyes with and without ERM following implantation of an EDOF-IOL [8]. Previous studies have reported that patients with pseudophakic rhegmatogenous retinal detachment (RRD) after previous multifocal IOL implantation achieved good functional outcomes at 12 months postoperatively [9,10]. Building on these encouraging findings this prospective study presents data on patient satisfaction and visual function of a non-diffractive, EDOF-IOL (Vivity, Alcon, Fort Worth, TX, USA) in eyes that developed cataract after pars plana vitrectomy (PPV) for RRD repair. Methods Design This prospective, single-site, non-comparative, interventional investigator-initiated trial was conducted at the Department of Ophthalmology at the University Eye Hospital in Ulm, Germany. The study was approved by the local ethics committee (Number 428/22), registered with the German clinical study register (DRKS00037029) and adhered to the tenets of the Declaration of Helsinki. Written informed consent for the study was obtained from each patient before proceeding with the study protocol. Inclusion and Exclusion Criteria Phakic patients who developed cataract after successful PPV for RRD repair were offered the opportunity to participate in the study. A time from RRD repair to cataract surgery of a minimum of 3 months was mandatory to avoid conflict with potential late re-detachment of the retina. Previous foveal involving RRD was possible if duration of foveal involvement was ≤ 3 days before RRD repair and there was no significant disintegration of retinal layers or thinning of ganglion cell layer (GCL) or decreased retinal thickness as compared to the partner eye that led suspect to significant retinal visual impairment. Further inclusion criteria were attached retina at least 3 months after PPV, history of a best-corrected distance visual acuity between 0.3 and 0.7 logMAR during follow-up after RRD repair, and an IOL implantation possible within the range of the IOL (10–30 D in 0.5-D steps, toric models T2–T6). Exclusion criteria were high ametropia (AL ≤ 21 mm or AL ≥ 28.5 mm), high corneal astigmatism (> 3 D), corneal pathologies, epiretinal macular membrane stage 3 and 4 according to Govetto et al. [11], glaucoma, uveitis, retinal artery/vein occlusion history, prior anti-VEGF therapy, severe disorganization of retinal layers (outer retina layers), decreased thickness as compared to the partner eye upon optical coherence tomography, ocular trauma history, amblyopia or better eye conditions. Study Protocol Patients were screened not before 3 months after a successful PPV for relevant cataract and then offered cataract surgery on the vitrectomized eye (primary eye) with implantation of an EDOF-IOL (Vivity, Alcon, Fort Worth, TX, USA). Target refraction was emmetropia in all cases. Follow-up visits were scheduled 1–2 days, 7–14 days, 1–2 months, and 4–6 months after surgery. Cataract surgery on the fellow eye was performed only at the patient’s request and after an extensive preoperative examination including fundus biomicroscopy, laser treatment of any retinal breaks or degenerative lesions [12]. Furthermore, detailed preoperative consultation included the increased relative risk of RRD of the fellow eye [13]. Baseline examinations included corrected and uncorrected distance visual acuity (CDVA, UDVA), slit lamp examination with fundus biomicroscopy after pupil dilation, measurement of intraocular pressure (Goldmann tonometry), topography (for evaluation of corneal astigmatism; Pentacam, Oculus), macular OCT (Cirrus-OCT, Carl Zeiss Meditec or Spectralis OCT; Heidelberg Engineering), optical biometry (IOL Master 700, Carl Zeiss Meditec) and power calculation with the Barrett Universal Formula, pupillometry (Nidek AR-K1S) and microperimetry (MAIA). A follow-up was recorded only for eyes that received surgery (macula-on, macula-off, and partner eyes that received clear lens exchange). No follow-up is available for the 10 partner eyes that remained phakic. Follow-up examinations included a complete slit lamp examination, IOP measurement, macular OCT, and CDVA and UDVA. Additional examinations at the last follow-up included monocular corrected and uncorrected distance (4 m), intermediate (66 cm) and near (40 cm) visual acuity (UDVA, UIVA, UNVA, CDVA, DCIVA, DCNVA) and binocular UDVA, UIVA, and UNVA. All visual acuities were obtained with Snellen optotypes at 4 m under photopic conditions from trained personnel in our study center. A defocus curve was also obtained from the same trained personnel with the patient wearing the correction that provided the CDVA in each eye at 4 m distance and introducing defocus by adding + 3 D to − 4 D in 1-D increments. All visual acuities were converted to logMAR for statistical analysis purposes. Patient-reported outcomes and spectacle independence were measured either at the 6-month visit after primary eye surgery in unilateral implantation and at the 6-month visit after second eye surgery in bilateral implantation. The German versions of standardized validated questionnaires (IOLSAT [14] and Catquest-9SF [15]) were used. Halos and glare were evaluated using a monitor-based vision simulator (Vision Simulator, ViSU-L GmbH, Hannover, Germany), which has been previously employed in similar studies [16]. This test provides a visual depiction and allows manual adjustment of halo and glare size and intensity on a scale from 0 to 100, with zero corresponding to the lowest score (no halos, no glare) and 100 to the highest score (severe halos and glare). The patients were asked to adjust the level of halo and glare size and intensity in the simulator to create the most accurate depiction of their subjective perception in their daily life. The test was performed under mesopic light conditions and at 66 cm from the monitor. All authors were involved in the baseline and follow-up examinations. Surgical Procedure Four experienced cataract surgeons (EV, CW, MP, and AW) performed standard micro-incisional cataract surgery with phacoemulsification (S4, Oertli or Constellation, Alcon) under topical anesthesia. The surgeons implanted the non-toric or toric EDOF-IOLs into the intact capsular bag in all cases. For toric IOL implantation the Callisto eye image-guided, markerless system was used for precise positioning. Study Outcomes The primary study outcome was monocular CDVA at 6 months after cataract surgery in the primary eye in comparison to preoperative CDVA. The secondary outcomes included monocular DCIVA, DCNVA, UDVA, UIVA, UNVA and binocular UDVA, UIVA, and UNVA. Exploratory parameters included defocus curve, patient satisfaction, and halo/glare results. Sample Size Calculation Prior to the study, a sample size calculation was performed using G*Power 3.1 [17]. Using a paired t test and assuming a mean improvement of 0.2 logMAR in CDVA after cataract surgery in comparison to baseline and a standard deviation of 0.33 based on a previous study of ours [10], we calculated for an alpha error of 0.05 a sample size of 24 eyes to achieve a power of 0.8. With an expected dropout rate of 2–3 patients, the planned enrolment was set at 27 patients. Statistical Analysis Statistical analysis was performed using SPSS 29.0 software (IBM Corp., Armonk, NY, USA). The normal distribution of variables was assessed using the Smirnov–Kolmogorov test. Depending on the distribution, parametrical or non-parametrical tests were performed, as indicated in the specific results section. Results are presented as mean ± standard deviation. Results Demographics Forty-three eyes (27 vitrectomized eyes with previous RRD, 13 with foveal involvement) from 27 patients (11 female, 16 male) underwent uneventful phacoemulsification with in-the-bag implantation of the EDOF-IOL. The mean age at time of cataract surgery of the primary eye was 60 ± 6 years. Sixteen patients underwent bilateral and 11 underwent unilateral surgery. Nine patients with macular involvement opted for bilateral implantation and four for unilateral, whereas in eyes without macular involvement the patients were equally distributed with seven opting for bilateral and seven for unilateral surgery. Among the 16 patients who underwent bilateral EDOF-IOL implantation, 13 achieved a BCVA better than 0.1 logMAR in the first operated eye at 4 weeks postoperatively. The mean time between PPV and cataract surgery was 6 ± 3 months. Preoperative mean axial length (AL) was 24.9 ± 1.4 mm, mean anterior chamber depth (ACD) 3.4 ± 0.3 mm, mean flat keratometry 41.2 ± 2.0 D, mean steep keratometry 42.1 ± 2.1 D. A toric version EDOF-IOL was implanted in 19 eyes (11 vitrectomized). Visual Acuity A follow-up was recorded only for eyes that received surgery (macula-on, macula-off, and partner eyes that received clear lens exchange). Monocular UDVA and CDVA in the primary eye improved statistically significantly after cataract surgery and further stabilized over the first six 6 months after surgery (p < 0.001 for all comparisons, Wilcoxon). Monocular CDVA remained stable after cataract surgery in the fellow eye, but UDVA improved statistically significantly (p = 0.002, Wilcoxon), as the refractive error was set to emmetropia (Table 1). Figure 1 demonstrates improvement in visual acuity, spherical equivalent, and refractive astigmatism.Table 1Development of corrected and uncorrected distant visual acuity throughout the follow-up period for primary (vitrectomized) eyes and fellow eyesTimepointPrimary eye (n = 27)Fellow eye (n = 16)CDVA (logMAR)UDVA (logMAR)CDVA (logMAR)UDVA (logMAR)Before ppV1.15 ± 0.97Before Phaco0.35 ± 0.161.01 ± 0.34− 0.01 ± 0.110.48 ± 0.441 day0.20 ± 0.190.27 ± 0.240.08 ± 0.150.17 ± 0.181 week0.08 ± 0.160.20 ± 0.23− 0.01 ± 0.080.07 ± 0.101 month0.05 ± 0.110.20 ± 0.220.00 ± 0.100.05 ± 0.146 months0.03 ± 0.120.16 ± 0.19− 0.03 ± 0.080.01 ± 0.11CDVA corrected distant visual acuity, UDVA uncorrected distant visual acuity, ppV pars plana vitrectomy, Phaco cataract surgeryFig. 1Standard six-graph template demonstrating improvement in visual acuity, spherical equivalent, and refractive astigmatism. UDVA uncorrected distant visual acuity, CDVA corrected distant visual acuity Table 1Development of corrected and uncorrected distant visual acuity throughout the follow-up period for primary (vitrectomized) eyes and fellow eyesTimepointPrimary eye (n = 27)Fellow eye (n = 16)CDVA (logMAR)UDVA (logMAR)CDVA (logMAR)UDVA (logMAR)Before ppV1.15 ± 0.97Before Phaco0.35 ± 0.161.01 ± 0.34− 0.01 ± 0.110.48 ± 0.441 day0.20 ± 0.190.27 ± 0.240.08 ± 0.150.17 ± 0.181 week0.08 ± 0.160.20 ± 0.23− 0.01 ± 0.080.07 ± 0.101 month0.05 ± 0.110.20 ± 0.220.00 ± 0.100.05 ± 0.146 months0.03 ± 0.120.16 ± 0.19− 0.03 ± 0.080.01 ± 0.11CDVA corrected distant visual acuity, UDVA uncorrected distant visual acuity, ppV pars plana vitrectomy, Phaco cataract surgery Development of corrected and uncorrected distant visual acuity throughout the follow-up period for primary (vitrectomized) eyes and fellow eyes CDVA corrected distant visual acuity, UDVA uncorrected distant visual acuity, ppV pars plana vitrectomy, Phaco cataract surgery Standard six-graph template demonstrating improvement in visual acuity, spherical equivalent, and refractive astigmatism. UDVA uncorrected distant visual acuity, CDVA corrected distant visual acuity Upon stratification by implantation type in the unilateral group UDVA improved from 0.96 ± 0.25 logMAR at baseline to 0.26 ± 0.25 at day 1, 0.15 ± 0.14 and month 1 and 0.15 ± 0.16 at 6 months. CDVA changed from 0.36 ± 0.14 to 0.19 ± 0.23, 0.06 ± 0.11, and 0.02 ± 0.13 logMAR, respectively. In the group that underwent bilateral implantation UDVA of the primary eye was 1.06 ± 0.39 logMAR at baseline, 0.27 ± 0.24 at day 1, 0.23 ± 0.26 at month 1, and 0.17 ± 0.22 at 6 months. Similarly, CDVA changed from 0.35 ± 0.18 to 0.21 ± 0.16, 0.04 ± 0.12, and 0.04 ± 0.12, respectively. At 6 months of follow-up, upon stratification by implantation type, UIVA, UNVA, DCIVA, and DCNVA were 0.52 ± 0.15, 0.62 ± 0.25, 0.61 ± 0.3, and 0.68 ± 0.29 logMAR in the unilateral group, and 0.39 ± 0.12, 0.37 ± 0.15, 0.49 ± 0.12, and 0.54 ± 0.19 logMAR in the primary eye of the bilateral group, respectively. In the 16 partner eyes that underwent clear lens exchange, UDVA was 0.01 ± 0.11 logMAR, UIVA 0.46 ± 0.08 logMAR, and near visual acuity 0.45 ± 0.09 logMAR. Figure 2 demonstrates corrected and uncorrected visual acuities with regard to macular state in primary eyes and fellow eyes. Binocular uncorrected visual acuity for the 16 patients that underwent binocular surgery was excellent for distance at − 0.04 ± 0.11 logMAR, and similar for intermediate and near visual acuity at 0.29 ± 0.10 logMAR and 0.26 ± 0.13 logMAR, respectively.Fig. 2Boxplots of corrected and uncorrected VA at different distances at 6 months with regard to macular state. VA visual acuity, UDVA uncorrected distant visual acuity, UIVA uncorrected intermediate visual acuity, UNVA uncorrected near visual acuity, CDVA corrected distant visual acuity, DCIVA distance corrected intermediate visual acuity, DCNVA distance corrected near visual acuity, Mac on macula on, Mac off macula off Boxplots of corrected and uncorrected VA at different distances at 6 months with regard to macular state. VA visual acuity, UDVA uncorrected distant visual acuity, UIVA uncorrected intermediate visual acuity, UNVA uncorrected near visual acuity, CDVA corrected distant visual acuity, DCIVA distance corrected intermediate visual acuity, DCNVA distance corrected near visual acuity, Mac on macula on, Mac off macula off Spherical Equivalent The spherical equivalent changed toward emmetropia in the primary eyes in a statistically significant way (p < 0.001; Wilcoxon), but not in the fellow eyes after surgery (p = 0.556; Wilcoxon). Spherical equivalent decreased between day 1 and day 7 and remained stable between first week and 6 months in the vitrectomized eyes. In the fellow eyes a further myopic shift of 0.11 D was observed (Table 2, Fig. 1).Table 2Development of manifest refraction throughout the follow-up period for primary (vitrectomized) eyes with regard to macular involvement and fellow eyesTimepointPrimary eye (n = 27)Fellow eye (n = 16)Macula onMacula offAllBefore Phaco− 2.71 ± 2.20− 4.32 ± 3.67− 3.49 ± 3.05− 0.60 ± 2.921 day0.31 ± 0.490.00 ± 0.520.17 ± 0.520.10 ± 0.371 week− 0.08 ± 0.51− 0.38 ± 0.69− 0.23 ± 0.61− 0.11 ± 0.181 month− 0.15 ± 0.54− 0.44 ± 0.78− 0.29 ± 0.67− 0.13 ± 0.446 months− 0.13 ± 0.54− 0.42 ± 0.80− 0.27 ± 0.68− 0.22 ± 0.51Macula on without macular involvement, Macula off with macular involvement, Phaco cataract surgery Table 2Development of manifest refraction throughout the follow-up period for primary (vitrectomized) eyes with regard to macular involvement and fellow eyesTimepointPrimary eye (n = 27)Fellow eye (n = 16)Macula onMacula offAllBefore Phaco− 2.71 ± 2.20− 4.32 ± 3.67− 3.49 ± 3.05− 0.60 ± 2.921 day0.31 ± 0.490.00 ± 0.520.17 ± 0.520.10 ± 0.371 week− 0.08 ± 0.51− 0.38 ± 0.69− 0.23 ± 0.61− 0.11 ± 0.181 month− 0.15 ± 0.54− 0.44 ± 0.78− 0.29 ± 0.67− 0.13 ± 0.446 months− 0.13 ± 0.54− 0.42 ± 0.80− 0.27 ± 0.68− 0.22 ± 0.51Macula on without macular involvement, Macula off with macular involvement, Phaco cataract surgery Development of manifest refraction throughout the follow-up period for primary (vitrectomized) eyes with regard to macular involvement and fellow eyes Macula on without macular involvement, Macula off with macular involvement, Phaco cataract surgery Defocus Curve The defocus curve of macular-on, macula-off eyes, and fellow eyes after clear lens exchange was comparable throughout the whole diopter span, with fellow eyes achieving a slightly better visual acuity (Fig. 3).Fig. 3Defocus curve of vitrectomized eyes with regard to macular state and fellow eyes Defocus curve of vitrectomized eyes with regard to macular state and fellow eyes Patient Satisfaction Patient satisfaction was very high in all cases. Two patients reported non-severe disturbing visual phenomena. One patient reported halos and glare in both eyes, while the other only halos in the eye with previous RRD. Both patients had undergone vitrectomy due to macula-off RRD. None of the other patients reported any disturbing visual phenomena in the “simulator” test. Six months after surgery, the results of the validated German version of the Catquest-9SF questionnaire revealed that with the exception of very near vision activities (e.g., handicrafts, reading) satisfaction with daily life activities was high (Fig. 4a). Overall 37% of patients responded that they were “very satisfied” and 56% responded that they were “fairly satisfied” with their overall vision (Supplemental Material 1). Furthermore, upon stratification by implantation type, more patients that underwent bilateral EDOF-IOL implantation demonstrated no difficulties with near-distance activities, such as reading and handicraft, whereas those with unilateral implantation exhibited no difficulties in higher percentage in far distance activities such as walking and recognizing faces (Supplemental Material 2).Fig. 4Results of the standardized questionnaires (Catquest-9SF and IOLSAT) after intraocular lens implantation. a Results of the German Catquest-9SF questionnaire in specific daily life activities. b Spectacle independence through intraocular lens satisfaction questionnaire (IOLSAT) in bright (BL) and dim light (DL) conditions at 6 months after implantation of IOL. “In the past 7 days, how often did you need to wear eyeglasses to see in bright light/dim light conditions”? (0 = never; 1 = rarely; 2 = sometimes; 3 = most of the time; 4 = all the time). Percentages of patients who answered “never” or “rarely” are highlighted Results of the standardized questionnaires (Catquest-9SF and IOLSAT) after intraocular lens implantation. a Results of the German Catquest-9SF questionnaire in specific daily life activities. b Spectacle independence through intraocular lens satisfaction questionnaire (IOLSAT) in bright (BL) and dim light (DL) conditions at 6 months after implantation of IOL. “In the past 7 days, how often did you need to wear eyeglasses to see in bright light/dim light conditions”? (0 = never; 1 = rarely; 2 = sometimes; 3 = most of the time; 4 = all the time). Percentages of patients who answered “never” or “rarely” are highlighted The IOLSAT questionnaire reveals the percentage of patients who report the use of spectacles categorized by distance (far, intermediate, or near) and lighting conditions (dim or bright) (Fig. 4b). The EDOF-IOL exhibited high spectacle independence for distance vision, which decreased at intermediate distances and was lowest for near tasks. Spectacle dependence was found to be greater under dim light than under bright light conditions across all distances. Interestingly, when stratified by implantation type, eyes that underwent bilateral implantation demonstrated markedly higher spectacle independence across all distances (Supplemental Material 3). Adverse Events Three patients developed new retinal breaks in the fellow eye 4 to 6 weeks postoperatively and received slit lamp-based laser coagulation. Two of the patients completed the 6-month follow-up without any further treatment or symptoms. However, one of them developed a RRD without macular involvement 6 weeks after surgery and underwent PPV at first day of symptoms, leaving visual acuity unaffected in the postoperative period. One patient in the primary eye developed a postoperative cystoid macular edema 4 weeks after surgery. It resolved with parabulbar steroids (40 mg triamcinolone) and topical NSAIDS, resulting in a CDVA of 0.0 logMAR. No other adverse events were observed during the study period. Discussion While the use of non-diffractive EDOF-IOLs in eyes with cataracts resulting from PPV for RRD is questionable evidence in this area is limited [9, 18]. To the best of our knowledge, this is the first prospective study that investigated satisfaction and visual function of a non-diffractive EDOF-IOL in these eyes. Our cohort yielded good visual and refractive outcomes, and comparable defocus curve between RRD and fellow eyes, and high patient satisfaction in eyes after successful RRD repair. Our data demonstrate a significant postoperative improvement in CDVA and UDVA in vitrectomized eyes, aligning with previous studies indicating favorable EDOF-IOL outcomes in compromised eyes [7,8, 10, 19]. As expected, UDVA improved significantly in the healthy fellow eyes as refractive error was eliminated [20]. UNVA and UIVA outcomes were adequate, with UNVA being slightly lower than UIVA. Yet, our cohort demonstrated lower UNVA and UIVA than usually reported in literature for regular cataract or refractive lens exchange [20,21]. UIVA was significantly worse in the fellow eye compared to the primary eye. This finding is counterintuitive, as one might expect similar or better uncorrected outcomes in eyes without prior retinal surgery. We attribute this finding to the higher myopic spherical equivalent in the primary vitrectomized eye compared to the smaller myopic error in the fellow eye. Furthermore, mini-monovision with this IOL showed very good functional results with very good UDVA, UIVA and good UNVA in other studies and might help to overcome these limitations [21,22]. In the majority of cases, normal eyes have been reported to experience a hyperopic shift between 1 month and 3 years postoperatively [23]. However, other studies report a decrease of the spherical equivalent over the first weeks [24]. In our study, at first day postoperatively a slight hyperopia was observed, mainly due to corneal edema. Between 1 week and 6 months the myopic change was just 0.04 D in the vitrectomized eyes and 0.11 D in the fellow eyes, which is consistent with previous studies [25]. This slight myopic shift is minor and clinically irrelevant in the vitrectomized eyes. On the contrary, the change of − 0.11 D in the fellow eyes is higher, though still insignificant. Postoperative refractive changes are primarily due to minor alterations in the capsular bag or corneal curvature. In the non-vitrectomized eyes, we hypothesize that the minor myopic shift of 0.11 D is driven by a slight anterior displacement of the IOL supported by the intact vitreous body; in contrast, vitrectomized eyes demonstrated a nominal myopic shift of just 0.04 D. Interestingly, the standard deviation of manifest refraction was higher in vitrectomized eyes than in fellow eyes, a finding that has been previously reported [26,27]. While the myopic shift is clinically marginal, this study underscores that postoperative refractive error may vary more in vitrectomized eyes than in fellow eyes [26]. The comparable defocus curves between primary and fellow eyes supports the functional range of vision, even in eyes with a history of macula-off RRD repair. This is consistent with our previous work, which confirmed that the defocus curve can be preserved even in macula-off RRD eyes, though still worse for macula-off eyes [10]. Presbyopia correcting IOLs have led to a rise in patient interest. Enhanced monofocal IOLs offer a lower-risk alternative in patients by improving intermediate vision over standard monofocal lenses without increasing halo or glare [28]. However, EDOF-IOLs provide a broader functional range, particularly for intermediate and near vision, at the cost of a modestly higher rate of photic phenomena [29,30]. While this trade-off should be weighed carefully because of the elevated risk of visual disturbances in eyes after RRD repair, the overall suitability of these IOLs remains a subject of debate in the presence of underlying retinal pathologies, with a recent review advising against the use of multifocal IOL in those patients [18]. Nevertheless, the use of non-diffractive EDOF-IOL in eyes with early-stage age-related macular degeneration or epiretinal membrane was connected to satisfactory outcomes [6, 19]. In this context adequate preoperative screening for certain more potentially favorable biomarkers within a disease entity needs to be underscored [9, 31,32]. Previous work demonstrated that a deficit in contrast sensitivity in degenerative diseases was associated with INL thinning. Long-term follow-up of OCT parameters after RRD repair demonstrates rather stable INL while IPL seems to remain a bit thickened [33,34] It is important to emphasize that our results are contingent upon the study’s strict inclusion criteria, which required, for example, an intact ellipsoid zone confirmed by preoperative OCT and timely RRD repair [35,36]. Patient satisfaction with the Vivity IOL was notably high, with a low incidence of reported disturbing photic phenomena that was connected to macula-off RRD and consistent with previous reports in eyes without accompanying retinal pathology [20, 37,38]. Overall 93% of patients reported being either very or fairly satisfied with their vision, a finding that was also observed in other studies that reported high satisfaction levels for daily life activities, with near vision tasks scoring lower in the CATQUEST-9SF questionnaire [39]. Of note, many of the studies in patient-reported outcomes report on patients after bilateral IOL implantation, while in our population there was a proportion of patients implanted in one eye only, as a result of the increased risk of RRD after cataract surgery in these particular patients. Interestingly, patients with bilateral implantation showed higher spectacle independency across all distances, but patients with unilateral implantation exhibited higher scores in far distance activities. Our cohorts near vision scores are lower than reported in literature elsewhere. Accordingly, most patients in our study reported minimal dependence on glasses for distance and intermediate activities, but nearly 50% required glasses for near activities as expected for EDOF-IOL from other studies’ data [20,21, 39] and underscores the trade-off between visual quality and range that persists with EDOF technologies. It therefore seems that a mini-monovision strategy of − 0.75 D may result in greater spectacle independence [40], which could eventually be a viable option for post-RRD eyes. The safety profile of surgical procedure of cataract surgery is generally reassuring, with a low rate of adverse events directly attributable to the IOL. However, two new retinal breaks and one RRD in the fellow eye highlight the significant risk of RRD under these surgical circumstances [13]. Thorough preoperative retinal examination, patient counseling, and education are critical. A recent study indicates that, despite their previous experience, patients with a prior RRD often wait too long to seek treatment for a subsequent RRD in the fellow eye [41]. Prophylactic laser coagulation for fellow eyes with identifiable degenerative lesions mitigates the risk of RRD [12]. In our cohort, as a result of close monitoring and comprehensive patient education, all three of the 16 patients who underwent bilateral surgery presented to the clinic within 1 day of symptom onset. However, the follow-up period of 6 months is rather short, limiting the long-term safety profile of the procedure in this cohort. Longer follow-up in these patients is necessary to draw clear conclusions regarding the RRD risk in the fellow eyes and the long-term safety profile. Other complications included a case of postoperative cystoid macular edema, which is a known complication of cataract surgery [42], which was successfully resolved with established treatment [43]. The major strengths of this study are its prospective design, the inclusion of eyes with both macula-on and macula-off RRD and the adequate sample size. However, limitations include its single-site, non-comparative design, the short 6-month follow-up, and the absence of contrast sensitivity testing. Furthermore, the lack of a monofocal control group limits our ability to determine whether the visual outcomes observed are specifically attributable to the EDOF design rather than to cataract surgery itself. These limitations prevent long-term assessment of outcome stability and late-onset complications, especially considering the high relative risk of RRD in the fellow eye. Future studies with larger sample sizes and longer follow-up periods are warranted to further solidify these findings and explore the long-term stability of refractive outcomes and visual performance in this specific patient population. Conclusion This study strengthens our previous findings [10] regarding the use of EDOF-IOLs in eyes after RRD repair and establishes the preoperative parameters that must be considered. The significant improvement in visual acuity, high patient satisfaction, and acceptable safety profile suggest that the Vivity EDOF-IOL could be a viable option with careful patient selection. However, bilateral implantation should be approached with caution because of the increased risk of RRD. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 352 KB) Supplementary file1 (PDF 352 KB)